Questionnaire finalized

EC4 logo EC4 Questionnaire

USE AND IMPLEMENTATION OF CARDIAC MARKERS IN ACUTE CORONARY SYNDROME AND HEART FAILURE


1. Country


2. Name of the hospital


3. Address of the hospital


4. Your name


5. Your phone number


6. Your email


7. Type of hospital

University hospital
Central hospital
District hospital
Primary care hospital

8. Does your hospital provide 24-hour admission of patients?

Yes
No

9. Do you have a separate chest pain unit (for less than 12 hours stay)?

Yes
No

10. Do you have an emergency unit (for more than 12 hours stay)?

Yes
No

11. Do you have a coronary care unit?

Yes
No

12. Number of patients with suspected acute coronary syndrome (suspected heart attack) admitted per year

< 500
500 - 999
1000 - 1500
> 1500
data not available

13. Number of patients with final diagnosis of acute myocardial infarction (ICD codes I21-I22) per year

< 500
500 - 999
1000 - 1500
> 1500
data not available

14. Laboratory service availability

24 hours a day
working hours only

15. Which biochemical tests do you offer for acute coronary syndrome? (you can tick more than one)

Total CK (creatinine kinase)
CK-MB mass
CK-MB activity
total CK / CK-MB ratio
CK isoforms
AST (aspartate aminotransferase)
LDH (lactate dehydrogenase)
HBD (hydoxybutyrate dehydrogenase)
Troponin-I
Troponin-T
Myoglobin
Other (please specify)

16. What is your preferred marker for diagnostic purposes? (tick only one)

Total CK
CK-MB mass
CK-MB activity
total CK / CK-MB ratio
CK isoforms
AST
LDH
HBD
Troponin-I
Troponin-T
Myoglobin
Other (please specify)

17. Do you usually combine your preferred marker with other cardiac markers at your hospital?

Yes
No

18. If you answered yes to the previous question, select these markers from the following list.

CK
CK-MB mass
CK-MB activity
total CK / CK-MB ratio
CK isoforms
AST
LDH
HBD
Troponin-I
Troponin-T
Myoglobin
other (please specify)

19. Does your laboratory plan any changes regarding the biochemical markers of acute myocardial infarction in the near future? If yes, please describe.

Yes
No

20. Does your laboratory plan any changes regarding the decision limits of the biochemical markers in the near future? If yes, please describe.

Yes
No

21. Do you have a written protocol for acute coronary syndrome / use of cardiac markers?

Yes
No

22. If applicable, is the protocol different for emergency unit / chest pain unit?

Yes
No

23. Were these protocols written in collaboration with the clinicians?

Yes
No

24. Do you measure Troponin I? If no, go to question 38.

Yes
No

25. How many Troponin I test do you analyse per year?

< 1000
1000 - 5000
5000 - 10000
> 10000

26. Troponin I test name

Access, Beckman Coulter
Advia Centaur, Bayer
AiO, Innotrac
Architect, Abbott
AxSym, Abbott
Dimension R&L, Dade Behring
Elecsys, Roche
Immulite 2000, DPC
immulite 2500, DPC
Immulite, DPC
IMx, Abbott
Liaison, DiaSorin
Stratus CS, Dade Behring
Tosoh AIA
Triage, Biosite
Vidas, bioMerieux
Vitros ECi
Other, please specify below

27. For which clinical situation do you measure TroponinI?

Diagnosis of myocardial infarction
Risk stratification
Infarct size estimation
Other, please specify below

28. Which sample type do you use

Heparin plasma
EDTA plasma
Serum

29. How is the test assayed?

stat
routine
batch
usually in batches but can be done stat if required

30. If batches, how often are these run per day?

Once
Two times
Three times
More often

31. What is the turn-around time for routine requests (sample received in the lab to the validated result):

< 30 minutes
< 60 minutes
< 90 minutes
< 120 minutes
< 180 minutes
> 180 minutes

32. What is the turn-around time for emergency requests:

< 30 minutes
< 60 minutes
< 90 minutes
< 120 minutes
> 120 minutes

33. What is the decision limit?


34. Was the decision limit determined by...

Assay imprecision (concentration at 10% CV)
Reference interval (99th percentile of the value distribution)
ROC curve
Other (please specify)

35. The decision limits (cut-offs) were chosen by:

Assay package insert information
Validation according to IFCC / NACB Recommendation 1999
ESC / ACC consensus statement 2000
Peer-reviewed literature
Age and gender related reference limits
Locally derived decision / reference limits

36. Do you have any criteria regarding frequency of testing and number of samples to be collected? If yes, please specify.

Yes
No

37. Do you have external quality assessment?

No external quality assessment
National quality assessment
European quality assessment
International quality assessment

38. Do you measure Troponin T? If no, go to question 52.

Yes
No

39. How many Troponin T tests do you analyse per year?

< 1000
1000 - 5000
5000 - 10000
> 10000

40. Troponin T test name

Cardiac-reader, Roche
Elecsys, Roche
Modular E, Roche
Troponin T sens., Rapid Test, Roche
Other, please specify below

41. For which clinical situation do you measure Troponin T?

Diagnosis of myocardial infarction
Risk stratification
Infarct size estimation
Other, please specify below

42. Which sample type do you use

Heparin plasma
EDTA plasma
Serum

43. How is the test assayed?

stat
routine
batch
usually in batches but can be done stat if required

44. If batches, how often are these run per day?

Once
Two times
Three times
More often

45. What is the turn-around time for routine requests (sample received in the lab to the validated result)?

< 30 minutes
< 60 minutes
< 90 minutes
< 120 minutes
< 180 minutes
> 180 minutes

46. What is the turn-around time for emergency requests?

< 30 minutes
< 60 minutes
< 90 minutes
< 120 minutes
> 120 minutes

47. What is the decision limit?


48. Was the decision limit determined by...

Assay imprecision (concentration at 10% CV)
Reference interval (99th percentile of the value distribution)
ROC curve
Other (please specify)

49. The decision limits (cut-offs) were chosen by:

Assay package insert information
Validation according to IFCC / NACB Recommendation 1999
ESC / ACC consensus statement 2000
Peer-reviewed literature
Age and gender related reference limits
Locally derived decision / reference limits

50. Do you have any criteria regarding frequency of testing and number of samples to be collected? If yes, please specify.

Yes
No

51. Do you have external quality assessment?

No external quality assessment
National quality assessment
European quality assessment
International quality assessment

52. Referring to cardiac disease, do you measure total CK? If no, go to question 67.

Yes
No

53. How many total CK tests do you analyse per year?

< 1000
1000 - 5000
5000 - 10000
> 10000

54. Assay traceability (e.g. IFCC recommended method)


55. Assay temperature

25 degrees C
30 degrees C
37 degrees C

56. Total CK test name

Abbott
Abbott Aeroset
Abbott QuickStart
ABX Diagnostics
ABX Pentra
Alpha Diagnostics
AMP Diagnostics
Audit Diagnostics
Bayer
Bayer 1-reag.-system
Bayer Advia
Bayer Express
Beckman Coulter
Biocon
Biocon Biozyme
Biomed
bioMerieux
BioSystems
Chema
Cormay
Dade Behring Dimension
Diagnosticum
Diagon
Diasys
Greiner
Hospitex
Human
IL Test
Konelab
Linear Chemicals
Merck
Olympus
Pars Azmon
Pointe Scientific
Randox
Reflotron
Roche
Roche Cobas Integra
Rolf Greiner BioChemica
SGM
Spotchem
Thermo Trace
Vitros 250-950 and 5
Vitros DT 60
Other, please specify below

57. Which sample type do you use

Plasma
Serum

58. How is the test assayed?

stat
routine
batch
usually in batches but can be done stat if required

59. If batches, how often are these run per day?

One
Two
Three
More

60. What is the turn-around time for routine requests (sample received in the lab to the validated result)?

< 30 minutes
< 60 minutes
< 90 minutes
< 120 minutes
< 180 minutes
> 180 minutes

61. What is the turn-around time for emergency requests?

< 30 minutes
< 60 minutes
< 90 minutes
< 120 minutes
> 120 minutes

62. What is the decision limit for its application in patients with acute coronary syndrome? Specify type of clinical application: diagnosis, monitoring, infarct size, etc.


63. Was the decision limit determined by...

Reference values: upper reference limit
Reference values: multiple of upper reference value. (Please specify)
ROC curve
Other (Please specify)

64. The decision limits (cut-offs) were chosen by:

Assay package insert information
Peer-reviewed literature
Locally derived decision / reference limits

65. Do you have any criteria regarding frequency of testing and number of samples to be collected? If yes, please specify.

Yes
No

66. Do you have external quality assessment?

No external quality assessment
National quality assessment
European quality assessment
International quality assessment

67. Do you measure CK-MB mass? If no, go to question 81.

Yes
No

68. How many CK-MB mass test do you analyse per year?

< 1000
1000 - 5000
5000 - 10000
> 10000

69. CK-MB mass test name

Access, Beckman Coulter
Advia Centaur, Bayer
AiO, Innotrac
Architect, Abbott
AxSym, Abbott
Dimension R&L, Dade Behring
Elecsys, Roche
Immulite, DPC
Immulite 2000, DPC
immulite 2500, DPC
Liaison, DiaSorin
Modular E, Roche
Stratus CS, Dade Behring
Tosoh AIA
Triage, Biosite
Vidas, bioMerieux
Vitros ECi, Ortho
Other, please specify below

70. For which clinical situation do you measure CK-MB mass?

Diagnosis of myocardial infarction
Risk stratification
Infarct size estimation
Re-infarction
Other, please specify

71. Which sample type do you use

Plasma
Serum

72. How is the test assayed?

stat
routine
batch
usually in batches but can be done stat if required

73. If batches, how often are these run per day?

Once
Two times
Three times
More often

74. What is the turn-around time for routine requests (sample received in the lab to the validated result)?

< 30 minutes
< 60 minutes
< 90 minutes
< 120 minutes
< 180 minutes
> 180 minutes

75. What is the turn-around time for emergency requests?

< 30 minutes
< 60 minutes
< 90 minutes
< 120 minutes
> 120 minutes

76. What is the decision limit for its application in patients with acute coronary syndrome? Specify type of clinical application: diagnosis, monitoring, infarct size, etc.


77. Was the decision limit determined by...

Reference values: upper reference limit
Reference values: multiple of URL. (Please specify)
ROC curve

78. The decision limits (cut-offs) were chosen by:

Package insert
Validation according to IFCC/NACB Recommendation 1999
ESC/ACC consensus statement 2000
Peer-reviewed literature
Age and gender related reference limits
Locally derived decision/reference limits

79. Do you have any criteria regarding frequency of testing and number of samples to be collected? If yes, please specify.

Yes
No

80. Do you have external quality assessment?

No external quality assessment
National quality assessment
European quality assessment
International quality assessment

81. Do you measure CK-MB activity? If no, go to question 94.

Yes
No

82. How many CK-MB activity tests do you analyse per year?

< 1000
1000 - 5000
5000 - 10000
> 10000

83. CK-MB activity test name

Electrophoresis
Immunoinhibition
Vitros 250-950, Ortho
Dimension, Dade Behring
Other, please specify below

84. Which sample type do you use

Plasma
Serum

85. How is the test assayed?

stat
routine
batch
usually in batches but can be done stat if required

86. If batches, how often are these run per day?

Once
Two times
Three times
More often

87. What is the turn-around time for routine requests (sample received in the lab to the validated result)?

< 30 minutes
< 60 minutes
< 90 minutes
< 120 minutes
< 180 minutes
> 180 minutes

88. What is the turn-around time for emergency requests?

< 30 minutes
< 60 minutes
< 90 minutes
< 120 minutes
> 120 minutes

89. What is the decision limit?


90. Was the decision limit determined by...

Reference values: upper reference limit
Reference values: multiple of URL. (Please specify)
ROC curve

91. The decision limits (cut-offs) were chosen by:

Package insert
Peer-reviewed literature
Locally derived decision/reference limits

92. Do you have any criteria regarding frequency of testing and number of samples to be collected? If yes, please specify.

Yes
No

93. Do you have external quality assessment?

No external quality assessment
National quality assessment
European quality assessment
International quality assessment

94. Do you measure myoglobin? If no, go to question 108.

Yes
No

95. How many myoglobin tests do you analyse per year?

< 1000
1000 - 5000
5000 - 10000
> 10000

96. Myoglobin test name

Access, Beckman Coulter
Advia Centaur, Bayer
AiO, Innotrac
AxSym, Abbott
BN 2, Dade Behring
Cobas Integra, Roche
Elecsys, Roche
Immulite, DPC
Konelab, Thermo Electron
Liaison, DiaSorin
Modular E, Roche
Stratus CS, Dade Behring
Tina-Quant, Roche
Triage, Biosite
Vidas, bioMerieux
Vitros 250-950, Ortho
Other, please specify below

97. For which clinical situation do you measure myoglobin?

Diagnosis of myocardial infarction
Infarct size estimation
Reinfarction
Other, please specify below

98. Which sample type do you use

Plasma
Serum

99. How is the test assayed?

stat
routine
batch
usually in batches but can be done stat if required

100. If batches, how often are these run per day?

Once
Two times
Three times
More often

101. What is the turn-around time for routine requests (sample received in the lab to the validated result)?

< 30 minutes
< 60 minutes
< 90 minutes
< 120 minutes
< 180 minutes
> 180 minutes

102. What is the turn-around time for emergency requests?

< 30 minutes
< 60 minutes
< 90 minutes
< 120 minutes
> 120 minutes

103. What is the decision limit for its application in patients with acute coronary syndrome? Specify type of clinical application: diagnosis, monitoring, etc.


104. Was the decision limit determined by...

Reference values: upper reference limit
Reference values: multiple of URL. (Please specify)
ROC curve

105. The decision limits (cut-offs) were chosen by:

Package insert
Peer-reviewed literature
Locally derived decision/reference limits

106. Do you have any criteria regarding frequency of testing and number of samples to be collected? If yes, please specify.

Yes
No

107. Do you have external quality assessment?

No external quality assessment
National quality assessment
European quality assessment
International quality assessment

108. Number of patients with suspected heart failure admitted per year:

< 500
500 - 2000
2000 - 5000
> 5000
data not available

109. Number of patients with final diagnosis of heart failure per year:

< 500
500 - 2000
2000 - 5000
> 5000
data not available

110. Laboratory service availability:

24 hours a day
working hours only

111. Do your offer... If none go to the end.

BNP
NT-pro-BNP
none

112. For which type of population do you offer these tests?

outpatients
emergency department
coronary unit
other

113. Test name

Abbott
Bayer
Biosite
Roche
Other, please specify below

114. Which sample type do you use

Heparin plasma
EDTA plasma
Serum

115. How is the test assayed?

stat
routine
batch
usually in batches but can be done stat if required

116. If batches, how often are these run per day?

Once
Two times
Three times
More often

117. What is the turn-around time for routine requests (sample received in the lab to the validated result)?

< 30 minutes
< 60 minutes
< 90 minutes
< 120 minutes
< 180 minutes
> 180 minutes

118. What is the turn-around time for emergency requests?

< 30 minutes
< 60 minutes
< 90 minutes
< 120 minutes
> 120 minutes

119. What is the decision limit?


120. Was the decision limit determined by...

97.5% percentile
ROC curve
Other

121. Decision limits (cut-off) chosen by:

Assay package insert information
Peer-reviewed literature
Age and gender related reference limits
Locally derived decision/reference limits

122. Do you have any criteria regarding frequency of testing:

Do not repeat
Repeated within 6 h
Repeated within 12 h
Repeated within 24 h
Repeated within more than 24 h

123. Do you have external quality assessment?

No external quality assessment
National quality assessment
European quality assessment
International quality assessment